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MaBACKGROUND Thiazide and thiazide-like diuretic agents are being increasingly used at lower doses. Hydrochlorothi-
azide (HCTZ) in the 12.5-mg dose remains the most commonly prescribed antihypertensive agent in the United States.
OBJECTIVES This study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily, by 24-h ambulatory blood
pressure (ABP) monitoring and evaluated efﬁcacy. Because HCTZ has been perceived as a short-acting drug, a third
comparison with an extended-release formulation (HCTZ-controlled release [CR]) was added.
METHODS This 12-week comparative, double-blind, outpatient study randomized 54 patients with stage 1 hypertension
to receive either chlorthalidone, 6.25 mg, (n ¼ 16); HCTZ 12.5 mg (n ¼ 18); or HCTZ-CR 12.5 mg (n ¼ 20). ABP monitoring
was performed at baseline and after 4 and 12 weeks of therapy.
RESULTS All 3 treatments signiﬁcantly (p < 0.01) lowered ofﬁce BP at weeks 4 and 12 from baseline. At weeks 4 and 12,
signiﬁcant reductions in systolic and diastolic 24-h ambulatory and nighttime BP (p < 0.01) were observed with chlor-
thalidone but not with HCTZ. At weeks 4 (p ¼ 0.015) and 12 (p ¼ 0.020), nighttime systolic ABP was signiﬁcantly lower
in the chlorthalidone group than in the the HCTZ group. With HCTZ therapy, sustained hypertension was converted into
masked hypertension. In contrast to the HCTZ group, the HCTZ-CR group also showed a signiﬁcant (p < 0.01) reduction
in 24-h ABP. All 3 treatments were generally safe and well tolerated.
CONCLUSIONS Treatment with low-dose chlorthalidone, 6.25 mg daily, signiﬁcantly reduced mean 24-h ABP as well
as daytime and nighttime BP. Due to its short duration of action, no signiﬁcant 24-h ABP reduction was seen with HCTZ,
12.5 mg daily, which merely converted sustained hypertension into masked hypertension. Thus, low-dose chlorthalidone,
6.25 mg, could be used as monotherapy for treatment of essential hypertension, whereas low-dose HCTZ monotherapy is
not an appropriate antihypertensive drug. (Comparative Evaluation of Safety and Efﬁcacy of Hydrochlorothiazide CR
with Hydrochlorothiazide and Chlorthalidone in Patients With Stage I Essential Hypertension; CTRI/2013/07/003793)
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ABBR EV I A T I ON S
AND ACRONYMS
ABPM = ambulatory blood
pressure monitoring
BP = blood pressure
CR = controlled release
DBP = diastolic blood pressure
HCTZ = hydrochlorothiazide
SBP = systolic blood pressure
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38012.5 mg of hydrochlorothiazide per day
has no signiﬁcant antihypertensive effect
—P.F. Magee, E.D. Freis (1)H ydrochlorothiazide (HCTZ) hasbeen available for more thanone-half a century and remains
the most commonly prescribed antihyperten-
sive drug worldwide. In the United States
alone, >134.1 million prescriptions of HCTZ
were written in 2008 (2). More than one thirdof HCTZ prescriptions (i.e., 48 million) were written
for monotherapy. Over more than 3 decades, the
prescription pattern of HCTZ has been heavily in-
ﬂuenced by the 8 reports of the Joint National
Committee (JNC) for Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure, all of
which recommended “thiazides” or “thiazide-like
drugs” or “thiazide-type diuretics” as ﬁrst-line or
preferred therapy for hypertension. For most prac-
ticing physicians, the term “thiazide” simply means
HCTZ (3). The more recent JNC reports also increas-
ingly have recommended low-dose thiazide and
thiazide-like diuretics as initial therapy in hyperten-
sive patients. Although a clinical study 30 years ago
showed that a dose of 12.5 mg of HCTZ per day hadSEE PAGE 390no signiﬁcant antihypertensive effect (1), this dose
remains the one most frequently prescribed in
monotherapy, and hypertension remains, by far,
its most common indication (2). However, despite
its widespread use, and in contrast to chlorthali-
done, little if any evidence is available regarding
the efﬁcacy and safety of HCTZ for the treatment
of essential hypertension, particularly at the dose
of 12.5 mg (4–6). Almost a decade ago, Carter
et al. (7) found signiﬁcant pharmacokinetic and
pharmacodynamic differences between HCTZ and
chlorthalidone. Chlorthalidone was found to be
approximately 1.5 to 2.0 as potent as HCTZ and
to have a much longer duration of action. Subse-
quently, Ernst et al. (8) compared effects of HCTZ
with those of chlorthalidone in the daily doses of
25 mg (forced titrated to 50 mg) and 12.5 mg (force
titrated to 25 mg), respectively, on ambulatory
blood pressure (ABP) and ofﬁce blood pressure
(BP). In the present study, we scrutinized the anti-
hypertensive efﬁcacy of HCTZ, 12.5 mg daily, as
assessed by 24-h ABP monitoring (ABPM), and
compared it with low-dose (6.25 mg) chlorthalidone
in patients with stage 1 essential hypertension.
Because the antihypertensive efﬁcacy of HCTZ may
be hampered by its short half-life, a third arm,with an extended-release formulation (HCTZ-
controlled release [CR]), was added.
METHODS
TRIAL DESIGN. This was a double-blind, double-
dummy, randomized, parallel group, comparative,
multicentric study conducted in Indian patients. The
study was initially planned in 213 patients with stage 1
hypertension randomized in a 1:1:1 ratio to receive
chlorthalidone, 6.25 mg tablets, or HCTZ-CR, 12.5 mg,
tablets, or conventional HCTZ, 12.5-mg tablets. Be-
tween December 2012 and February 2015, only 54 pa-
tients were enrolled in the study. The reason for this
slow recruitmentwas difﬁculty in getting patientswith
stage 1 hypertension at tertiary centers.
The study was carried out according to Good Clin-
ical Practice guidelines and the Declaration of Hel-
sinki. The study protocol was approved by the ethics
committee at each of the participating centers,
namely, KEM Hospital Research Centre, Ethic Com-
mittee (Pune, India); Institutional Clinical Ethics
Committee at Rajiv Gandhi Medical College and
Chhatrapati Shivaji Maharaj Hospital (Thane, India);
Medilink Ethics Committee (Ahmadabad, India);
Aadhya Independent Ethics Committee (Ahmadabad,
India); Ofﬁce of the Principal and Controller, Institu-
tional Ethics Committee at Dr. S.N Medical College
(Jodhpur, India); and Omega Ethical Committee
(Mangalore, India). The Drug Controller General of
India also approved the study protocol. All patients
were provided with an oral explanation of the nature
of the study and study drugs by the investigator at
each center. The patient information sheet was pro-
vided in a language understood by the patient, and
patients who provided written consent to participate
were screened for the study.
SELECTION CRITERIA. Male and female patients be-
tween 18 and 65 years of age were eligible if they had
stage 1 essential hypertension (ofﬁce systolic blood
pressure [SBP] between 140 and 159 mm Hg and dia-
stolic blood pressure [DBP] between 90 and
99 mm Hg). As recommended in European Society of
Hypertension/European Society of Cardiology hyper-
tension guidelines (9) and 2 other guidelines (10,11),
the hypertension was diagnosed on the basis of ofﬁce
BP and conﬁrmed by 24-h ABPM measurements.
Exclusion criteria (among others) were secondary
hypertension; diabetes; hyperuricemia; gout; chronic
kidney disease; parathyroid diseases; recent cardio-
vascular disease or cardiovascular accident; abnormal
renal function (serum creatinine: >1.5 mg/dl; blood
urea nitrogen [BUN]: >20 mg/dl), abnormal liver
function (aspartate aminotransferase [AST], alanine
FIGURE 1 Disposition of Study Participants
Assessed for eligibility (N = 150)
Washout period (N = 137)
Randomized (N = 54)
Hydrochlorothiazide CR
12.5 mg (n = 20)
Hydrochlorothiazide
12.5 mg (n = 18)
Chlorthalidone
6.25 mg (n = 16)
Excluded (n = 13)
Lost to follow up = 5
Eligibility criteria not satisfied = 4
Consent withdrawn = 3
Refused treatment = 1
Excluded (n = 83)
Eligibility criteria not satisfied = 53
Visit deviation = 10
Lost to follow up = 9
Consent withdrawn = 4
Did not cooperate = 3
Refused treatment = 2
Adverse experience = 1
Premature study termination = 1
Protocol Violation (n = 2)
Urinary tract infection and high
  chloride at screening = 1
Incorrect randomization = 1
Discontinued patients (n = 7)
Adverse Experience (n = 1) at
  -     Week 4 = 1
Failure to return for follow up (n = 2) at
  -     Week 4 = 1
  -     Week 6 = 1
Insufficient therapeutic response at
  -     Week 4 = 2
Patient refused treatment (n = 2) from
  -     Week 2 = 1
  -     Week 4 = 1
Study completed as per protocol (n = 11)
Protocol Violation (n = 2)
Non responder still continued = 1
Left ventricular hypertrophy = 1
Discontinued patients (n = 8)
Administrative/other (n = 1) at
  -     Week 10 = 1
Failure to return for follow up (n = 2) at
  -     Week 2 = 1
  -     Week 4 = 1
Insufficient therapeutic response (n = 2) at
  -     Week 2 = 1
  -     Week 4 = 1
Patient refused treatment (n = 2) from
  -     Week 1 = 2
Did not cooperate (n = 1) at
  -     Week 12 = 1
Study completed as per protocol (n = 8)
Protocol Violation (n = 2)
High serum bilirubin value = 1
High chloride value = 1
Discontinued patients (n = 5)
Adverse Experience (n = 1) at
  -     Week 8 = 1
Insufficient therapeutic response (n = 2) at
  -     Week 4 = 2
Patient refused treatment (n = 2) from
  -     Week 0 = 1
  -     Week 6 = 1
Study completed as per protocol (n = 9)
Analyzable/ITT (n = 20) Analyzable/ITT (n = 18) Analyzable/ITT (n = 16)
CR ¼ controlled release; ITT ¼ intention-to-treat.
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381aminotransferase [ALT], total bilirubin, or alkaline
phosphatase >2.5 the upper limit of normal values);
electrolyte imbalance; hypercalcemia; and hypo-
phosphatemia. Women who were pregnant, lactating,
or of childbearing potential and not practicing
contraception were also excluded from the study, as
were alcoholics or patients who had participated in a
clinical trial within 30 days prior to enrollment.
TREATMENT AND STUDY PROCEDURES. Patients
with stage 1 essential hypertension were subjected to
a 2-week placebo washout period. Post completion ofthe washout period, 24-h ABPM was performed at the
baseline visit. A 24-h ABP machine (Bravo model
monitor; Suntech Medical, Raleigh, North Carolina)
was used to perform 24-h ABP measurements. Eligible
patients were randomized to receive treatment with a
once-daily dose of chlorthalidone, 6.25 mg, or
HCTZ-CR, 12.5 mg, or conventional HCTZ, 12.5-mg
tablets for 12 weeks. Patients were instructed to take
the study medicines in the morning.
Evaluations comparing efﬁcacy were performed at
baseline and weeks 4 and 12 for 24-h ABPM and at
baseline and weeks 2, 4, 8, and 12 for ofﬁce BP
TABLE 1 Demographic and Baseline Disease Characteristics of Enrolled Patients
Hydrochlorothiazide-CR
(n ¼ 20)
Hydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
Total
(N ¼ 54) p Value
Sex*
Male 10 (50.0) 8 (44.44) 9 (56.25) 27 (50.0) 0.915
Female 10 (50.0) 10 (50.0) 7 (43.75) 27 (50.0)
Age, yrs† 46.8  11.77 47.72  10.37 41.13  13.40 45.44  11.96 0.348
BMI, kg/m2† 26.89  3.75 27.81  5.08 26.61  4.12 27.14  4.31 0.613
Waist circumference, m† 0.81  0.27 0.89  0.22 0.90  0.18 0.87  0.23 0.508
SBP, mm Hg† 148.82  5.73 149.87  4.50 147.38  4.59 148.74  5.02 0.437
DBP, mm Hg† 92.03  2.48 93.39  2.45 93.94  2.84 93.05  2.66 0.062
Smoking status*
Current smoker 1 (5.0) 2 (11.11) 1 (6.25) 4 (7.41) 0.775
Former smoker 1 (5.0) - 2 (12.50) 3 (5.56) 0.598
Never smoked 18 (90.00) 16 (88.89) 13 (81.25) 47 (87.04) 0.612
Values are n (%) or mean  SD. *Chi-square test or Fisher exact test was used for comparison, as appropriate. †Kruskal-Wallis test was used for comparison.
BMI ¼ body mass index; CR ¼ controlled release; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
TABLE 2 Change in
Outcome
Ambulatory SBP
Change at week 4*
p value†
Change at week 12*
p value†
Ambulatory DBP
Change at week 4*
p value†
Change at week 12*
P value†
Values are mean  SD. *Kru
calculated from baseline va
SBP was signiﬁcantly lowe
(125.52 vs. 139.71mmHg, re
This analysis was perform
study.
Abbreviations as in Tabl
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382measurements. At each visit, physical examination
and safety assessment were performed; and vital
signs, details of concomitant medications, and
compliance to study drug were recorded. The inves-
tigator instructed and educated the patient on diet
and exercise at all visits.
BLINDING AND RANDOMIZATION TECHNIQUES. Pa-
tients were randomized to 1 of the 3 treatment arms
according to the randomization chart provided by the
sponsor. Randomization codes were generated using
block randomization technique. The number of
blocks was calculated on the basis of block size and
number of patients assigned to each center.
To eliminate evaluation bias, the study used a
double-blind, double-dummy design. All patients
received an active drug along with placebos matchingMean Systolic and Diastolic Ambulatory Blood Pressure Levels
Hydrochlorothiazide-CR
(n ¼ 20)
Hydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
11.05  11.91 2.95  10.24 7.49  10.24
0.001 0.426 0.001
10.27  11.78 6.02  12.46 11.14  12.41
0.002 0.104 <0.001
7.73  9.05 2.83  8.02 5.82  8.29
0.001 0.104 0.003
8.21  9.79 4.17  8.15 7.78  9.74
0.002 0.058 0.007
skal-Wallis test used with Dunn’s test for multiple comparisons; all change values are
lues. †Comparison between baseline and Wilcoxon signed rank test results. Mean 24-h
r for the chlorthalidone group than for the hydrochlorothiazide group at week 4
spectively, p¼0.019) andweek 12 (121.87 vs. 136.64mmHg, respectively, p¼0.013).
ed in an intention-to-treat population that included all patients randomized in the
e 1.the other 2 drugs. Each site was provided with a
sealed envelope that contained individual, patient-
speciﬁc envelopes with details of the treatment
assigned to that particular patient. Investigators were
instructed to open this envelope only in case of an
emergency or serious adverse events.
EFFICACY. The primary efﬁcacy parameter was the
change in mean 24-h ambulatory SBP and DBP
from baseline to weeks 4 and 12. Secondary efﬁcacy
parameters were changes in mean ofﬁce SBP and DBP
and changes in mean ambulatory daytime and night-
time SBP and DBP from baseline to weeks 4 and 12.
Ofﬁce BP measurements were performed according
to standard guidelines for measurement of BP by
sphygmomanometer. For 24-h ABPM, BP was recor-
ded every 15 min during the day (i.e., 6 AM to 10 PM)
and every 30 min during the night (i.e., from 10 PM to
6 AM). For ABP readings to be considered evaluable, at
least 2 readings per hour during the daytime and at
least 1 reading per hour during the nighttime were
required. At week 4, patients were evaluated
for response to their treatment. Patients with BP
>140/90 mm Hg after 4 weeks of therapy were
considered nonresponders. Nonresponders were
considered treatment failures and were excluded
from the study.
SAFETY. Patients who provided written consent for
participation were evaluable for safety assessment. At
baseline and at the end-of-therapy visit, tests for
routine hematology (hemoglobin, platelet count, red
blood cell count, white blood cell count, differential
count, erythrocyte sedimentation rate, packed cell
volume, mean corpuscular volume), biochemistry
(AST, ALT, alkaline phosphatase, bilirubin, albumin,
globulin, total proteins, BUN, serum creatinine,
FIGURE 2 Mean Change From Baseline to Week 12 in Average Ambulatory SBP
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HCTZ 12.5mg (n = 18) CTD 6.25mg (n = 16)
CTD ¼ chlorthalidone; HCTZ ¼ hydrochlorothiazide; SBP ¼ systolic blood pressure.
TABLE 3 Change in Mean Ofﬁce SBP and DBP Between Weeks 4 and 12 From Baseline
Outcome
Hydrochlorothiazide-CR
(n ¼ 20)
Hydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
Ofﬁce SBP
Week 0* 148.82  5.73 149.87  4.50 147.38  4.59
Week 4* 137.48  11.10 137.00  10.40 132.19  9.98
Change at week 4* 11.34  11.34 12.87  9.96 15.19  10.14
p value† <0.001 <0.001 <0.001
Week 12* 133.38  15.16 134.57  12.36 130.98  14.94
Change at week 12* 15.43  14.49 15.30  11.87 16.40  15.38
p value† <0.001 <0.001 0.002
Ofﬁce DBP
Week 0* 92.03  2.48 93.39  2.45 93.94  2.84
Week 4* 85.38  7.75 85.39  6.42 84.18  8.23
Change at week 4* 6.65  7.33 8.00  6.12 9.76  8.48
p value† 0.001 <0.001 <0.001
Week 12* 86.18  8.50 85.23  6.85 84.44  9.47
Change at week 12* 5.85  8.44 8.16  6.42 9.50  10.39
p value† 0.006 <0.001 0.005
Values are mean  SD. *Kruskal-Wallis test was used with Dunn’s test for multiple comparisons; all changes were
calculated from baseline values. †Comparison with baseline, and Wilcoxon signed rank test was used for com-
parison. Analysis was performed in an intent-to-treat population that included all patients randomized in the
study.
Abbreviations as in Table 1.
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383serum potassium, uric acid, calcium, phosphorous,
sodium, chloride), lipid proﬁle (high-density lipo-
protein, low-density lipoprotein [LDL], very
low-density lipoprotein, triglycerides, total choles-
terol), random blood glucose, and routine urinalysis
were performed. Electrocardiograms were recorded at
screening, baseline and at weeks 4 and 12. Urine
pregnancy tests were performed at the screening
visit, the baseline visit, and the end-of-therapy visit
for all female patients of childbearing potential.
STATISTICAL METHODS. A sample size of 71 patients
per group was estimated to show the difference of at
least 5 mm Hg in mean fall of SBP among groups to
demonstrate HCTZ-CR was superior to HCTZ and
noninferior to chlorthalidone, with a power of 80% at
the 5% level of signiﬁcance and considering 20%
dropouts.
Data were analyzed on the basis of an intention-to-
treat (ITT) population that included all subjects who
were randomized according to the randomization
schedule provided by the sponsor. The approach of
last observation carried forward was used to impute
missing assessments.
Descriptive statistics were used to compare de-
mographic and baseline disease characteristics. All
patients were compared at baseline for homogeneity
using the Kruskal-Wallis test for continuous variables
and the chi-square test or Fisher exact test, as
appropriate, for categorical variables.
Data were not normal due to the small sample size.
Hence, nonparametric tests were used for analysis.The primary endpoint was the comparative change in
mean 24-h ambulatory SBP and DBP values from
baseline to weeks 4 and 12. Secondary endpoints were
comparative changes in mean ofﬁce SBP and DBP
values at weeks 4 and 12 from baseline and in mean
ambulatory daytime and nighttime SBP and DBP
values from baseline to weeks 4 and 12.
FIGURE 3 Visit-to-Visit Fall in Ofﬁce SBP
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384All previously mentioned continuous parameters
were assessed using the Kruskal-Wallis test with
Dunn’s multiple comparison. The Wilcoxon signed
rank sum test was used for within-group com-
parisons. All categorical parameters were assessed
using the chi-square test or Fisher exact test, as
appropriate.
The safety population consisted of all patients who
provided written informed consent for participation
in the study. Safety parameters consisted of adverse
events and changes in laboratory parameters from
baseline to end-of-therapy visit. Percentages of pa-
tients who reported an adverse event were compared-Visit Fall in Ofﬁce DBP
ek 2 At Week 4 At Week 8 At Week 12
Visits
g (n =20) HCTZ 12.5 mg (n = 18) CTD 6.25 mg (n = 16)
* *
* *
** **
**
** **
*
.01; Wilcoxon signed rank test was used for comparisons.
d pressure; other abbreviations as in Figures 2 and 3.using the chi-square test or Fisher exact test, as
appropriate. Changes in laboratory parameters were
assessed by Wilcoxon signed rank sum tests for
within-group comparison and Kruskal-Wallis tests for
between-group comparisons. For all statistical tests,
the signiﬁcance level was 0.05. All analyses were
performed using SAS version 9.3 software (SAS Insti-
tute, Inc., Cary, North Carolina).
RESULTS
PATIENTS. Of the 150 patients screened, 137 patients
satisfying the eligibility criteria were put on placebo
washout for 2 weeks (Figure 1). After completion of
washout period, 54 eligible patients were enrolled in
the study and randomized to receive either chlor-
thalidone, 6.25 mg (n ¼ 16), HCTZ-CR, 12.5 mg
(n ¼ 20), or HCTZ, 12.5 mg (n ¼ 18). Demographic and
baseline disease characteristics were generally
matched and were not signiﬁcantly different among
treatment groups (Table 1).
EFFICACY. Pr imary efﬁcacy parameter . Changes
in mean 24-h ambulatory SBP and DBP values are
shown in Table 2 and Figure 2. Patients treated with
chlorthalidone and HCTZ-CR showed a signiﬁcant
reduction in 24-h ambulatory SBP and DBP values from
baseline (p < 0.01). At weeks 4 and 12, this reduction
was not statistically signiﬁcant for patients treated
with conventional HCTZ. At weeks 4 (p ¼ 0.019) and
12 (p ¼ 0.013), the 24-h ambulatory SBP was signiﬁ-
cantly lower in patients treated with chlorthalidone
than those treated with conventional HCTZ.
Secondary efﬁcacy parameters . Changes in mean
ofﬁce SBP and DBP are shown in Table 3 and
Figures 3 to 5. At weeks 4 and 12, all 3 treatments
showed a signiﬁcant reduction in mean ofﬁce SBP
(HCTZ: p< 0.001; HCTZ-CR: p< 0.001; chlorthalidone:
p ¼ 0.002) and DBP (HCTZ: p ¼ 0.006; HCTZ-CR:
p < 0.001; chlorthalidone: p ¼ 0.005). There were no
signiﬁcant differences in changes in ofﬁce SBP and
DBP from baseline at weeks 4 and 12 among treatment
groups, despite the numerically greater fall in BP in
chlorthalidone-treated patients.
A total of 6 patients (2 from each group) were
withdrawn from the study because of insufﬁcient
therapeutic response (p ¼ 0.999). The proportion of
patients who met BP goal levels (BP <140/90 mm Hg)
did not differ signiﬁcantly among treatment groups
(chlorthalidone: 62.5% vs. HCTZ-CR: 55% vs. con-
ventional HCTZ: 55.56%; p ¼ 0.847). Tighter BP con-
trol (BP: <130/80 mm Hg) was attained by 25.0% of
patients from the chlorthalidone group, 11.11% from
the conventional HCTZ group, and 15% from the
HCTZ-CR group. For all 3 treatments, signiﬁcantly
FIGURE 5 Visit-to-Visit Mean Ofﬁce SBP
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Abbreviations as in Figures 2 and 3.
TABLE 4 Changes in Ambulatory Daytime Mean SBP and DBP
Outcome
Hydrochlorothiazide-CR
(n ¼ 20)
Hydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
Ambulatory SBP
Change at week 4* 9.15  13.70 3.55  10.64 6.74  9.62
p value† 0.014 0.191 0.005
Change at week 12* 7.88  13.45 7.16  11.75 12.11  12.29
p value† 0.034 0.017 0.001
Ambulatory DBP
Change at week 4* 6.73  9.94 2.71  9.22 5.73  8.43
p value† 0.012 0.217 0.013
Change at week 12* 6.32  10.08 4.73  8.89 8.74  10.45
p value† 0.014 0.058 0.002
Values are mean  SD. *Kruskal-Wallis test used with Dunn’s test for multiple comparisons; all change values
were calculated from baseline values. †Comparison with baseline and Wilcoxon signed rank tests were used for
comparison. Mean 24-h SBP was signiﬁcantly lower for the chlorthalidone group than for the hydrochlorothiazide
group at week 12 (127.57 mm Hg vs. 141.90 mm Hg, respectively, p value ¼ 0.018). This analysis was performed
in an intent-to-treat population that included all patients randomized in the study.
Abbreviations as in Table 1.
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385lower ofﬁce SBP was observed at week 4 and main-
tained through week 12 (Figure 5).
CHANGE IN AMBULATORY DAYTIME BP. At week 12,
patients from all 3 treatment groups showed a sig-
niﬁcant reduction from baseline in ambulatory day-
time SBP (Table 4), whereas only patients from
the chlorthalidone and HCTZ-CR groups showed a
signiﬁcant reduction in ambulatory daytime DBP.
The reduction in mean ambulatory daytime SBP and
DBP values was not signiﬁcantly different among
treatment groups. At week 12, the mean ambulatory
daytime SBP was signiﬁcantly lower for patients
treated with chlorthalidone than for those treated
with conventional HCTZ (p ¼ 0.018).
CHANGE IN AMBULATORY NIGHTTIME BP. At week
12, patients from the chlorthalidone and HCTZ-CR
groups showed a signiﬁcant reduction from baseline
in ambulatory nighttime SBP (chlorthalidone:
p ¼ 0.002; HCTZ-CR: p < 0.001) and DBP (chlorthali-
done: p ¼ 0.001; HCTZ-CR: p ¼ 0.001) (Table 5).
However, this change was not signiﬁcant in patients
treatedwith conventional HCTZ. Atweeks 4 (p¼0.015)
and 12 (p ¼ 0.020), ambulatory nighttime SBP was
signiﬁcantly lower in patients treated with chlorthali-
done than in those treated with HCTZ.
SAFETY. All treatments were generally safe and
well tolerated. During the washout period, 2 pa-
tients reported 3 adverse events; and during the
treatment period, 26 patients reported a total of 48
adverse events (Table 6). All adverse events re-
ported during the washout period were of mild in-
tensity, and in the investigator’s opinion, most were
unlikely related to study drug. A total of 4 patients
(2 from the HCTZ-CR group, 1 from the conventional
HCTZ group, and 1 from the chlorthalidone group)
experienced borderline hypokalemia (deﬁned as
<3.5 mmol/l). No patient experienced hypona-
tremia. One patient from the HCTZ-CR group was
found to have increased blood glucose levels. Nine
patients (3 from the HCTZ-CR group, 4 from the
conventional HCTZ group, and 2 from the chlor-
thalidone group) showed increased uric acid levels.
At the end of the study, no signiﬁcant changes were
observed in total cholesterol, triglycerides, or
LDL-cholesterol levels.
DISCUSSION
Previous studies have evaluated the antihyperten-
sive efﬁcacy of chlorthalidone, 6.25 mg, on ofﬁce
BP, as monotherapy (12), as well as in combination
with losartan (13) and metoprolol (14). However,
no previous studies had evaluated and comparedthe 24-h BP-lowering efﬁcacy of chlorthalidone at a
dose of 6.25 mg.
OFFICE BP VERSUS 24-H ABP. The principal ﬁndings
of the present study are that the most commonly
prescribed antihypertensive drug, namely HCTZ, at
the dose of 12.5 mg daily failed to signiﬁcantly lower
24-h ABP after 12 weeks of monotherapy (Central
Illustration). In contrast, chlorthalidone in the very
low daily dose of 6.25 mg lowered 24-h ABP by
11.1/7.8 mm Hg (Central Illustration). Thus, whenever
the antihypertensive efﬁcacy of HCTZ is assessed by
ofﬁce BP measurement, it seems comparable to
that of chlorthalidone and other drug classes. This
TABLE 5 Changes in Ambulatory Nighttime Mean SBP and DBP
Outcome
Hydrochlorothiazide-CR
(n ¼ 20)
Hydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
Ambulatory SBP
Change at week 4* 12.94  13.25‡ 2.35  11.58 8.24  12.14
p value† <0.001 0.326 0.001
Change at week 12* 12.66  12.63 4.87  14.12 10.17  13.59
p value† <0.001 0.268 0.002
Ambulatory DBP
Change at week 4* 8.73  10.72 2.96  8.88 5.92  8.73
p value† 0.001 0.173 0.002
Change at week 12* 10.10  11.03 3.62  9.34 6.82  9.62
p value† 0.001 0.135 0.001
Values are mean  SD. *Kruskal-Wallis test was used with Dunn’s test for multiple comparisons; all change values
were calculated from baseline values. †Comparison with baseline, and Wilcoxon signed rank test was used for
comparison. ‡p ¼ 0.034 vs. hydrochlorothiazide group. Mean 24-h SBP was signiﬁcantly lower for the chlor-
thalidone group than for the hydrochlorothiazide group at week 4 (118.10 vs. 133.90 mm Hg, respectively, p
value ¼ 0.015) and week 12 (116.17 vs. 131.38 mm Hg, respectively, p value ¼ 0.020). This analysis was per-
formed in an intent-to-treat population that included all patients randomized in the study.
Abbreviations as in Table 1.
TABLE 6 Adverse Events Reported During Treatment
Adverse Event
Hydrochlorothiazide-CR
(n ¼ 20)
Clinical adverse events
Abdominal pain -
Abdominal pain, upper 1
Arthralgia 1
Asthenia -
Back pain -
Constipation 1
Diarrhea -
Dyspnea -
Dyspnea, paroxysmal nocturnal -
Dysuria -
Ear pain 1
Fatigue -
Gastritis 1
Headache 5
Insomnia 1
Nausea 2
Esophageal pain 1
Paresthesia 1
Restlessness 1
Tooth abscess -
Toothache -
Vomiting 1
Laboratory adverse events
Serum potassium decreased 2
Blood glucose increased 1
Blood uric acid increased 3
Pyuria 1
Urinary tract infection 2
Total 26
Number of patients* 12 (60.00)
*Values are n or n (%). p ¼ 0.686 using the chi-square test.
CR ¼ controlled release.
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386discrepancy between ABPM and ofﬁce BP indicates
that HCTZ lowers BP appropriately during daytime,
when patients are seen in the physician’s ofﬁce but
has little if any effect during the night and early
morning hours.
The consistent overestimation of the antihyper-
tensive response to HCTZ by ofﬁce BP measurements
has been shown in 3 previous studies. In the patient
population in the study by Finkielman et al. (15), the
difference between ofﬁce BP and 24-h ABP was 4.8/
2.1 mm Hg (p < 0.01) in 228 subjects treated with
HCTZ, 25 mg daily. This difference is very similar to
that found in our previous analysis (4.9/2.5 mm Hg) in
more than 16,000 patients (16). In the present study,
HCTZ lowered ofﬁce BP by 9.3/4.0 mm Hg more than
that of 24-h ABPM. In the study by Ernst et al. (8), the
reduction in SBP during nighttime hours was 13.5 
1.9 mm Hg for chlorthalidone versus 6.4  1.7
mm Hg for HCTZ (p > 0.01). Thus, 4 independentHydrochlorothiazide
(n ¼ 18)
Chlorthalidone
(n ¼ 16)
Total
(N ¼ 54)
1 1 2
- - 1
- - 1
1 - 1
1 1 2
- - 1
1 - 1
- 1 1
- 1 1
- 1 1
- - 1
1 - 1
- - 1
1 1 7
- - 1
- - 2
- - 1
- - 1
- - 1
- 1 1
- 1 1
- - 1
1 1 4
- - 1
4 2 9
- - 1
- - 2
11 11 48
8 (44.44) 6 (37.50) 26 (48.15)
CENTRAL ILLUSTRATION Low-Dose Thiazides in Hypertension:
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A signiﬁcant decrease of both 24-h and nighttime ambulatory BP with chlorthalidone,
6.25 mg/day, was observed. There was no signiﬁcant decrease with HCTZ, 12.5 mg/day.
**p < 0.001; *p < 0.01; Wilcoxon signed rank tests were used for comparison. CTD ¼
chlorthalidone; HCTZ ¼ hydrochlorothiazide; SBP ¼ systolic blood pressure.
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387studies have now documented the fact that assessing
the antihypertensive efﬁcacy of HCTZ by ofﬁce BP
measurements only is deceptive and prone to lull
physicians and patients into a false sense of security.
With HCTZ therapy, sustained hypertension merely
will be converted into masked hypertension. BP
seems to be well controlled during daytime, when
patients are seen in the ofﬁce. However, as shown in
Figure 2, late night-to-early morning BP remains
poorly controlled by HCTZ. Importantly, this time
period has been identiﬁed as the most critical in the
diurnal cycle because it coincides with the highest
risk of stroke and other cardiovascular events (17–19).
Over the past decades, JNC reports have increas-
ingly recommended low-dose thiazide diuretic agents
as initial therapy in hypertensive patients. For most
physicians, a “thiazide” is synonymous with HCTZ
(3). The National Heart, Lung, and Blood Institute has
continued to deceptively promote low-dose thiazides
on the basis of chlorthalidone data, although tacitly
aware that such promotion will only motivate physi-
cians to treat more and more patients with HCTZ (20).
The calamity of millions of patients being exposed to
an inefﬁcacious drug could have been avoided if the
advice of Maggie and Freis had been heeded,
approximately 3 decades ago (1). Many of us still
consider Dr. Freis to be the father of HCTZ.
In contrast to conventional HCTZ, chlorthalidone
(and HCTZ-CR) provides smooth BP control
throughout the diurnal cycle. Chlorthalidone pos-
sesses a distinct pharmacokinetic proﬁle, and its
longer and smoother duration of action may be due
to its wider volume of distribution, with partitioning
into red blood cells (21,22). The resulting sustained
antihypertensive effects, particularly throughout
the night and in the early morning hours, may
be the reason for chlorthalidone’s well-documented
beneﬁts for reduced cardiovascular morbidity and
mortality (23–25). Thus, it is not surprising that when
higher-dose–outcome data were compared, chlor-
thalidone proved superior to HCTZ (26,27). No
outcome data are available for HCTZ in doses of 12.5
to 25 mg/day (4,5). Although our study did not
evaluate the antihypertensive efﬁcacy of indapa-
mide, low-dose indapamide has been found effective
in treatment of patients with hypertension alone and
in those with comorbidities, such as renal insufﬁ-
ciency or diabetes (28,29).
With chronic kidney disease, thiazide diuretics
have been shown to be efﬁcacious in patients
with a glomerular ﬁltration rate of approximately
40 to 50 ml/min. Importantly, in a recent pilot study,
Agarwal et al. (30) documented the fact that chlor-
thalidone improved BP control, even in patientswith moderately advanced chronic kidney disease,
as deﬁned by glomerular ﬁltration rates between
20 and 45 ml/min/1.73 m2 (30).
SAFETY OF LOW-DOSE DIURETICS. Almost all
adverse effects of thiazide and thiazide-like diuretics
are dose-dependent (31,32). It is therefore not sur-
prising that, in the present study with low doses, few
if any adverse effects were seen. In an earlier 8-week
study by Ernst et al. (8), the incidence of hypokalemia
(potassium <3.5 mmol/l) was 50% with HCTZ, 25 mg,
and 46% with chlorthalidone, 12.5 mg. In our study,
the incidence was merely 10% (2 of 20 patients) with
HCTZ-CR, 12.5 mg; 5.6% (1 of 18 patients) with con-
ventional HCTZ 12.5 mg; and 6.3% (1 of 16 patients)
with chlorthalidone, 6.25 mg.
STUDY LIMITATIONS. This is a relatively small study
with a limited number of patients. Although the
decrease in ambulatory blood pressure differs among
the 3 drugs, no conclusion regarding outcome should
be drawn from these data. Outcome data have been
put forward in randomized controlled trials for
chlorthalidone (and indapamide) but not for low-dose
hydrochlorothiazide.
CONCLUSIONS
The present data show that because of its short
duration of action, HCTZ, one of the most widely
prescribed antihypertensive drugs, failed to lower
24-h ABP in its most common dose of 12.5 mg, thereby
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Treatment with low-dose
chlorthalidone, 6.25 mg daily, is more effective than
hydrochlorothiazide, 12.5 mg daily, in reducing
daytime, nighttime, and mean 24-h ambulatory blood
pressure over 4 to 12 weeks and can be prescribed as
initial therapy for treatment of hypertension, whereas
low-dose HCTZ should no longer be used.
TRANSLATIONAL OUTLOOK: The mere fact that
hydrochlorothiazide has been available for over
one-half a century and was prescribed to millions of
patients is not an acceptable document of its efﬁcacy.
Large, longer-term studies are needed to compare the
efﬁcacy and safety of low-dose chlorthalidone to that
of other thiazide diuretic agents.
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388converting sustained hypertension into masked hy-
pertension. In contrast, chlorthalidone, in the
very low dose of 6.25 mg daily, provided smooth BP
control throughout the diurnal cycle. Thus, low-dose
chlorthalidone, 6.25 mg, can be used as monotherapy,
whereas low-dose HCTZ should no longer be consid-
ered an acceptable option for treatment of essential
hypertension.
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